Glaucoma is the second leading cause of blindness in the world, according to the world health organization. Glaucoma\r\nwhen untreated leads to increased intra ocular pressure and possible loss of vision. Anti-glaucoma matrix type ocuserts of\r\nacetazolamide were designed using 32 factorial design to achieve prolonged therapeutic effect by improving residence time at\r\nthe site of the application. Independent variables selected were matrix forming polymer (X1) poly-?-caprolactone (PCL 37000)\r\nand polyethylene glycol (PEG 4000) as plasticizer (X2), dependent variables as cumulative drug release Q24hrs (Y1) and n value as\r\n(Y2). The central point (0, 0) was studied in quintuplicate. All other formulation and processing variables were kept in variant\r\nthroughout the study. Statistical optimization of polymer concentration by fitting it in factorial design was done. The main\r\npurpose of the study was to deliver the drug in zero order kinetics. Solvent casting technique was followed to prepare ocuserts.\r\nAll formulations were subjected to various physiochemical evaluations like thickness, uniformity of weight, swelling index,\r\nsurface pH, folding endurance, drug content, in-vitro drug release studies, release rate kinetics were investigated. One way\r\nanalysis of variance (ANOVA), regression analysis was performed. The ocular inserts were smooth and passed all the evaluation\r\ntests performed. The in-vitro kinetic treatment (zero order and korsemeyer�s regression value) and n values suggest that AB5\r\nwas the best formulation provided the desired in-vitro drug release for 48 hours.
Loading....